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ABSTRACT
Although targeted therapy for receptor tyrosine kinases (RTKs) of advanced 
gastric cancers (AGCs) has been in the spotlight, guidelines for the identification of 
RTK-amplified gastric cancers (RA-GCs) have not been established. In this study, 
we investigate clinicopathologic characteristics of RA-GCs and propose a screening 
algorithm for their identification. We performed immunohistochemistry (IHC) for MLH1, 
MSH2, PMS2, MSH6, key RTKs (EGFR, HER2, MET), and p53, in situ hybridization for 
Epstein-Barr virus encoding RNA, and silver in situ hybridization (SISH) for EGFR, HER2, 
and MET using tissue microarrays of 993 AGCs. On IHC, 157 (15.8%) 61, (6.15%), and 
85 (8.56%) out of 993 cases scored 2+ or 3+ for EGFR, HER2, and MET, respectively. 
On SISH, 31.2% (49/157), 80.3% (49/61), and 30.6% (26/85) of 2+ or 3+ cases 
on IHC showed amplification of the corresponding genes. Of the 993 cases, 104 were 
classified as RA-GCs. RA-GC status correlated with older age (P < 0.001), differentiated 
histology (P = 0.001), intestinal or mixed type by Lauren classification (P < 0.001), 
lymphovascular invasion (P = 0.026), and mutant-pattern of p53 (P < 0.001). The cases 
were divided into four subgroups using two classification systems, putative molecular 
classification and histologic-molecular classification, based on Lauren classification, 
IHC, and SISH results. The histologic-molecular classification showed higher sensitivity 
for identification of RA-GCs and predicted patient prognosis better than the putative 
molecular classification. In conclusion, RA-GCs show unique clinicopathologic features. 
The proposed algorithm based on histologic-molecular classification can be applied to 
select candidates for genetic examination and targeted therapy.
INTRODUCTION
Gastric cancer (GC) is one of the most common 
cancers in the world, especially in East Asian countries 
such as Korea and Japan [1]. Surgery with pre- or 
postoperative chemotherapy has been performed as a 
treatment option for advanced gastric cancers (AGCs). 
However, the majority of patients show poor prognosis 
and there are unmet clinical needs for this dismal disease 
[2, 3]. In this regard, targeted therapy that interferes 
with molecules associated with oncogenesis or disease 
progression represents a promising solution. In human 
patients with epidermal growth factor receptor 2 (HER2)-
overexpressing gastric cancer, combination treatment with 
trastuzumab, anti-HER2 antibody, and chemotherapy with 
cisplatin and fluoropyrimidine-based regimens resulted 
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in longer overall survival than chemotherapy alone [4]. 
Since this study, several clinical trials that targeted other 
receptor tyrosine kinases (RTKs) have been performed 
[5–8]. However, the majority of trials encountered difficult 
situations due to the rarity of the candidate population. 
Cases showing amplification of RTK genes only account 
for a small proportion of total GCs: 5-10% with epidermal 
growth factor receptor (EGFR), 6-17% with HER2, and 
6-12% with MET gene amplification [9–14].
According to The Cancer Genome Atlas (TCGA) 
research, GCs can be divided into four molecular 
subgroups: Epstein-Barr virus (EBV) positive, 
microsatellite instability (MSI), genome stable (GS), 
and chromosomal instability (CIN) [14]. Interestingly, 
the majority of GCs that overexpress RTKs belong to 
the CIN group, and GCs in the CIN group show unique 
characteristics of a higher rate of p53 mutation and 
mutual exclusiveness in the amplification of RTK genes 
[14]. With increasing interest in targeted therapy for 
GCs, it has become more important to identify cases 
showing amplification of the target genes associated with 
the specific therapy. Furthermore, considering the rarity 
of the candidate patients, it is mandatory to develop an 
adequate and robust platform that is clinically practicable. 
However, to our best knowledge, algorithms or guidelines 
to identify RTK-amplified gastric cancers (RA-GCs) 
and the CIN subgroup have not been established. In 
this study, we performed comparative analyses using 
immunohistochemistry (IHC) and in situ hybridization, 
which are clinically feasible assay platforms in 
terms of speed and cost effectiveness, to investigate 
clinicopathologic characteristics of RA-GCs. On the basis 
of these results, we propose a screening algorithm for the 
identification of RA-GCs.
RESULTS
Immunohistochemical profile of AGCs
Expression of mismatch repair (MMR) gene related 
proteins was evaluated in 990 cases. MMR-deficient GCs 
were found in 114 cases (11.5%). Simultaneous loss of 
expression of MLH1 and PMS2 was observed in 101 cases 
and co-loss of MSH2 and MSH6 was observed in 13 cases.
All 993 cases were evaluated for expression of 
EGFR, HER2, MET, and p53. The number of cases 
scored as 0, 1+, 2+, and 3+ respectively was 524 (52.8%), 
312 (31.4%), 119 (12.0%), and 38 (3.8%) for EGFR 
(Figure 1A to 1D); 846 (85.4%), 86 (8.7%), 29 (2.9%), 
and 32 (3.2%) for HER2 (Figure 1E to 1H); and 726 
(73.1%), 182 (18.3%), 67 (6.7%), and 18 (1.8%) for MET 
(Figure 1I to 1L). Thus, 157 (15.8%), 61 (6.1%), and 85 
(8.5%) cases were classified as positive for EGFR, HER2, 
and MET, respectively. In p53 IHC, 371 (37.4%) and 622 
(62.6%) cases were classified as wild-pattern and mutant-
pattern, respectively.
Clinicopathologic characteristics according EGFR, 
HER2 and MET IHC results are summarized in Table 1. 
EGFR positivity and HER2 positivity were more frequent 
in older patients (P = 0.003, and 0.013, respectively) and 
MET expression showed a similar tendency (P= 0.069). 
Positivity for each of the three RTKs was significant 
in AGCs with differentiated histology (P < 0.001 for 
EGFR and HER2; P = 0.032 for MET) and intestinal 
or mixed type by Lauren classification (P < 0.001 for 
all). Additionally, EGFR positivity was associated with 
male sex (P = 0.036), lower third location (P = 0.004), 
EBV encoding RNA in situ hybridization (EBER-ISH) 
negativity (P = 0.001), and MMR deficiency (P < 0.001). 
HER2 positivity was frequently observed in cases with 
p53 mutant-pattern (P = 0.009). MET positivity was 
associated with larger tumor size (> 5 cm, P = 0.041), 
presence of lymphovascular invasion (LVI, P = 0.025), 
lymph node metastasis (LNM, P = 0.030), and MMR 
deficiency (P < 0.001).
RTK gene amplification and EBV profile of 
AGCs
Among 2+ or 3+ cases for each RTK on IHC, 31.2% 
(49/157 cases), 80.3% (49/61 cases), and 30.6% (26/85 
cases) were revealed the amplifications of EGFR, HER2, 
and MET gene, respectively (Figure 1M to 1Q) on silver 
in situ hybridization (SISH). Co-amplification of RTK 
genes were observed in eighteen cases with following 
combinations: 7 cases with co-amplification of EGFR 
and HER2, 6 cases with co-amplification of EGFR and 
MET, 4 cases with co-amplification of HER2 and MET, 
and one case with co-amplification of all three RTK genes. 
Evaluation of EBER-ISH was available in 971 out of 993 
cases and 61 (6.3%) cases were EBV-positive.
Clinicopathologic characteristics of RA-GCs
Of 993 cases, 104 (10.5%) were identified as RA-
GCs, including 18 cases showing co-amplification. RA-
GCs showed unique clinicopathologic characteristics 
(Table 2); they were associated with older age (P < 0.001), 
differentiated histology (P = 0.001), intestinal or mixed 
type by Lauren classification (P < 0.001), presence of 
LVI (P = 0.026), and p53 mutant-pattern (P < 0.001). 
Among the 104 RA-GCs, 18 co-amplified AGCs showed 
no significant differences in clinicopathologic features 
compared to 86 RA-GCs without co-amplification 
(Supplementary Table S1).
Sensitivity for identifying RA-GCs according to 
classification system
We divided all AGC cases into four subgroups 
based on two classification systems: putative molecular 
and histologic-molecular classification. According to 
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the putative molecular classification, the 993 AGCs 
were composed of the following subgroups: 61 (6.1%) 
EBV-positive GCs, 114 (11.5%) MMR-deficient GCs, 
253 (25.5%) putative GS (pGS) GCs, and 565 (56.9%) 
putative CIN (pCIN) GCs. The histologic-molecular 
classification divided the AGCs into the following four 
subgroups: 61 (6.1%) EBV-positive GCs, 114 (11.5%) 
MMR-deficient GCs, 143 (14.4%) diffuse-putative GS 
(D-pGS) GCs, and 675 (68.0%) intestinal-putative CIN 
(I-pCIN) GCs.
Next, we compared putative molecular classification 
and histologic-molecular classification to investigate 
which system was superior for screening out RA-GCs. A 
correlation between RTK IHC positivity and I-pCIN group 
of histologic-molecular classification was significant 
(P < 0.001; Table 3). However, pCIN group of putative 
molecular classification was not. Both pCIN and I-pCIN 
groups correlated well with RTK amplification (P = 0.007 
and < 0.001, respectively, Table 3). I-pCIN group showed 
higher sensitivity (87.5%) for identifying RA-GCs than 
Figure 1: Immunohistochemical (IHC) staining and silver in situ hybridization (SISH) for EGFR, HER2, and MET. 
Representative microphotographs of negative, 1+, 2+, and 3+ cases for EGFR, HER2, and MET (A-D, EGFR; E-H, HER2; I-L, MET) 
with original magnification ×200. Representative cases of gene amplification for EGFR, HER2, and MET SISH (M-O) with original 
magnification ×400.
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pCIN group of putative molecular classification (74.0%) 
(Table 3). Therefore, when mining RTK amplified cases, 
the histologic-molecular classification was superior to 
putative molecular classification in this study. However, 
both pCIN and I-pCIN groups showed low specificity to 
find EGFR, HER2, or MET amplified-GCs (45.1% and 
34.3%, respectively, Table 3).
Survival analysis
Survival analysis was available for 979 of 993 
patients. Kaplan-Meier survival curves showed no 
significant differences in recurrence-free survival (RFS) 
and overall survival (OS) depending on RTK expression 
(Supplementary Figure S1A and S1B for EGFR IHC, 
Table 1: Clinicopathologic characteristics of advanced gastric cancers according to the expression status of EGFR, 
HER2, and MET
















(n = 157) (n = 836) (n = 61) (n = 932) (n = 85) (n = 908)
Age (years) 58.5 ± 10.7 55.7 ± 12.8 0.003 60.0 ± 10.7 55.9 ± 12.6 0.013 58.5 ± 10.7 55.9 ± 12.7 0.069
Sex Male 647 114 (72.6) 533 (63.8) 0.036 46 (75.4) 601 (64.5) 0.096 61 (71.8) 586 (64.5) 0.192
Female 346 43 (27.4) 303 (36.2) 15 (24.6) 331 (35.5) 24 (28.2) 332 (35.5)
Location Lower third 552 104 (66.2) 448 (53.6) 0.004 38 (62.3) 514 (55.2) 0.291 55 (64.7) 497 (54.7) 0.087
Upper and 
mid-third 441 53 (33.8) 388 (46.4) 23 (37.7) 418 (44.8) 30 (35.3) 411 (45.3)
Size ≤ 5 cm 495 70 (44.6) 425 (50.8) 0.164 31 (50.8) 464 (49.8) 0.896 33 (38.8) 462 (50.9) 0.041
> 5 cm 498 87 (55.4) 411 (49.2) 30 (49.2) 468 (50.2) 52 (61.2) 446 (49.1)
Differentiation Differentiated 281 70 (44.6) 211 (25.2) < 0.001 30 (49.2) 251 (26.9) < 0.001 33 (38.8) 248 (27.3) 0.032




mixed 518 125 (79.6) 393 (47.0) < 0.001 47 (77.0) 471 (50.5) < 0.001 73 (85.9) 445 (49.0) < 0.001
Diffuse 475 32 (20.4) 443 (53.0) 14 (23.0) 461 (49.5) 12 (14.1) 463 (51.0)
LVI Absent 704 102 (65.0) 602 (72.0) 0.085 40 (65.6) 664 (71.2) 0.383 51 (60.0) 653 (71.9) 0.025
Present 289 55 (35.0) 234 (28.0) 21 (34.4) 268 (28.8) 34 (40.0) 255 (28.1)
LNM Absent 275 44 (28.0) 231 (27.6) 0.919 15 (24.6) 260 (27.9) 0.576 15 (17.6) 260 (28.6) 0.030
Present 718 113 (72.0) 605 (72.4) 46 (75.4) 672 (72.1) 70 (82.4) 648 (71.4)
Pathologic T 
stage T2 163 26 (16.6) 137 (16.4) 0.012 9 (14.8) 154 (16.5) 0.385 11 (12.9) 152 (16.7) 0.208
T3 358 72 (45.9) 286 (34.2) 27 (44.3) 331 (35.5) 38 (44.7) 320 (35.2)
T4 472 59 (37.6) 413 (49.4) 25 (41.0) 447 (48.0) 36 (42.4) 436 (48.0)
p53 IHC Wild-type pattern 371 63 (40.1) 308 (36.8) 0.472 13 (21.3) 358 (38.4) 0.009 30 (35.3) 341 (37.6) 0.726
Mutant pattern 622 94 (59.9) 528 (63.2) 48 (78.7) 574 (61.6) 55 (64.7) 567 (62.4)
EBER-ISH * Negative 910 150 (99.3) 760 (92.7) 0.001 60 (98.4) 850 (93.4) 0.170 78 (94.0) 832 (93.7) 0.919
Positive 61 1 (0.7) 60 (7.3) 1 (1.6) 60 (6.6) 5 (6.0) 56 (6.3)
MMR protein 
IHC** MMR-proficient 876 112 (71.8) 764 (91.6) < 0.001 56 (91.8) 820 (88.3) 0.402 63 (75.0) 813 (89.7) < 0.001
MMR-deficient 114 44 (28.2) 70 (8.4) 5 (8.2) 109 (11.7) 21 (52.0) 93 (10.3)
Overall stage II 95 16 (10.2) 79 (9.4) 0.690 5 (8.2) 90 (9.7) 0.931 6 (7.1) 89 (9.8) 0.094
III 307 44 (28.0) 263 (31.5) 19 (31.1) 288 (30.9) 19 (22.4) 288 (31.7)
IV 591 97 (61.8) 494 (59.1) 37 (60.7) 554 (59.4) 60 (70.6) 531 (58.5)
LVI: lymphovascular invasion; LNM: lymph node metastasis; IHC: immunohistochemistry; EBER-ISH: Epstein-Barr virus encoding RNA in situ hybridization; MMR protein: 
mismatch repair gene related protein
* Evaluated in 971 cases
** Evaluated in 990 cases
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C and D for HER2 IHC, and E and F for MET IHC). 
In addition, the RFS and OS of patients with AGC 
showing any RTK positivity on IHC did not differ from 
the remaining groups (Supplementary Figure S1G and 
S1H). The prognosis of patients with AGC showing 
amplification of any of the three RTK genes also did 
Table 2: Clinicopathologic characteristics of advanced gastric cancers according to gene amplification status of three 
receptor tyrosine kinases (RTKs)
Category Variables No. of cases 
(n = 993)
RTK gene amplification* P-value
Positive (%) Negative (%)
(n = 104) (n = 889)
Age (years) 60.3 ± 9.7 55.6 ± 12.7 < 0.001
Sex Male 647 76 (73.1) 571 (64.2) 0.073
Female 346 28 (26.9) 319 (35.8)
Location Lower third 552 66 (63.5) 486 (54.7) 0.088
Upper and mid-third 441 38 (36.5) 403 (45.3)
Size ≤ 5 cm 495 52 (50.0) 443 (49.8) 0.974
> 5 cm 498 52 (50.0) 446 (50.2)
Histology Differentiated 281 44 (42.3) 237 (26.7) 0.001
Undifferentiated 712 60 (57.7) 652 (73.3)
Lauren classification Intestinal or mixed 538 90 (86.5) 448 (50.4) < 0.001
Diffuse 455 14 (13.5) 441 (49.6)
LVI Absent 704 64 (61.5) 640 (72.0) 0.026
Present 289 40 (38.5) 249 (28.0)
LNM Absent 275 26 (25.0) 249 (28.0) 0.516
Present 718 78 (75.0) 640 (72.0)
Pathologic T stage T2 163 19 (18.3) 144 (16.2) 0.140
T3 358 45 (43.3) 313 (35.2)
T4 472 40 (38.5) 432 (48.6)
p53 IHC Wild-type pattern 371 22 (21.2) 349 (39.3) < 0.001
Mutant pattern 622 82 (78.8) 540 (60.7)
EBER-ISH** Negative 910 100 (98.0) 810 (93.2) 0.057
Positive 61 2 (2.0) 59 (6.8)
MMR protein 
IHC*** MMR-proficient 876 96 (93.2) 780 (87.9) 0.113
MMR-deficient 114 7 (6.8) 107 (12.1)
Overall stage II 95 13 (12.5) 82 (9.2) 0.210
III 307 25 (24.0) 282 (31.7)
IV 591 66 (63.5) 525 (59.1)
LVI: lymphovascular invasion; LNM: lymph node metastasis; IHC: immunohistochemistry; EBV-ISH Epstein-Barr virus 
encoding RNA in situ hybridization; MMR protein: mismatch repair gene related protein
* Defined as amplification of any of EGFR, HER2 or MET in SISH
** Evaluated in 971 cases
*** Evaluated in 990 cases
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not vary significantly according to amplification status 
(Supplementary Figure S2A and S2B for EGFR, C and D 
for HER2, and E and F for MET). In addition, there were 
no significant differences in RFS and OS between RA-
GCs and non-RA-GCs (Supplementary Figure S3A and 
S3B) and no significant findings were observed in survival 
analysis after the separation of RTK co-amplified cases 
(Supplementary Figure S3C and S3D).
In the putative molecular classification, EBV-
positive and MMR-deficient subgroups showed longer 
RFS whereas pGS and pCIN subgroups showed relatively 
shorter RFS (P = 0.001); however, there was no significant 
difference in RFS between pGS and pCIN subgroups 
(P = 0.511, Figure 2A). In contrast, for histologic-
molecular classification, in addition to significant 
differences observed in comparison of entire subgroups 
(P = 0.001), the I-pCIN subgroup showed a trend toward 
longer RFS than the D-pGS subgroup (P = 0.069; 
Figure 2B). In multivariate analysis, D-pGS and I-pCIN 
subgroups of histologic-molecular classification were 
worse prognostic factors for RFS (p=0.012, HR 2.07 and 
p=0.014, HR 1.93, respectively) and OS (p=0.001, HR 
2.27 and p=0.002 HR 2.1, respectively) (Table 4).
Overall survival was different among subgroups 
for both classification systems (P = 0.001 for all; Figure 
2C and 2D). However, in multivariate analysis, individual 
subgroups of putative molecular classification did not 
have a prognostic impact on patient survival except for the 
pGS subgroup whereas the D-pGS and I-pCIN subgroups 
of histologic-molecular classification were revealed as 
unfavorable prognostic factors for patient survival (Table 4).
Proposed screening algorithm
On comparison of the two classification systems 
for IHC, histologic-molecular classification showed 
higher sensitivity for identifying RA-GCs than putative 
molecular classification. When considering the significant 
correlation between RTK IHC positivity and RTK gene 
amplification (Spearman’s correlation coefficient = 
0.576, P < 0.001), it is expected that histologic-molecular 
classification would identify more RA-GCs than putative 
molecular classification. Moreover, histologic-molecular 
classification can predict patient prognosis much better 
than putative molecular classification. On the basis of 
these findings, we proposed a screening algorithm for the 
identification of RA-GCs (Figure 3).
DISCUSSION
Several studies investigating target genes such as 
EGFR, MET, and fibroblast growth factor receptor (FGFR) 
have been conducted since the application of trastuzumab 
in the treatment of HER2-positive gastric cancer patients 
Table 3: RTK expression and amplification status according to classification systems
Classification 
system
Subgroup No. of 
cases(n = 993)










(n = 230) (n = 763) (n = 104) (n = 889)
Putative 
molecular
EBV-postive 61 5 (2.2) 58 (7.3) 0.003† 2 (1.9) 59 (6.6) 0.009†
MMR-deficient 114 51 (22.2) 63 (8.3) 7 (6.7) 107 (12.0)
pGS 253 47 (20.4) 206 (27.0) 0.208†† 18 (17.3) 235 (26.4) 0.007††
pCIN 565 127 (55.2)* 438 (57.4)** 77 (74.0)* 488 (54.9)**
Histoligic-
molecular
EBV-postive 61 5 (2.2) 58 (7.3) 0.003† 2 (1.9) 59 (6.6) 0.009†
MMR-deficient 114 51 (22.2) 63 (8.3) 7 (6.7) 107 (12.0)
D-pGS 143 11 (4.8) 132 (17.3) < 0.001†† 4 (3.8) 139 (15.6) < 0.001††
I-pCIN 675 163 (70.9)* 512 (67.1)** 91 (87.5)* 584 (65.7)**
MMR: mismatch repair gene related; pGS: putative genome stable; pCIN: putative chromosome instability; D-pGS: 
diffuse-putative genome stable; I-pCIN: intestinal-putative chromosome instability
†P-value for the comparison of EBV positive + MMR deficient vs. pGS + pCIN or vs. D-pGS + I-pCIN
††P-value for the comparison of pGS vs. pCIN or D-pGS vs. I-pCIN
*Sensitivity of pCIN and I-pCIN subgroup for the detection of RTK IHC positive case or RTK amplified case.
**Specificity of pCIN and I-pCIN subgroup for the detection of RTK IHC positive case or RTK amplified case: 100-(%)**.
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[11, 15–17]. Based on these studies, several targeted agents 
that interfere with RTKs have been developed and applied 
in clinical trials [18–20]. For clinical application and 
success of clinical trials, it is crucial to select candidates 
expected to show a response to the targeted agents, in 
particular, robustly and cost-effectively. The TCGA study 
[14], which was based on comprehensive molecular 
analysis, and a study by Cristescu et al. [21], which used 
transcriptome analysis, categorized GCs into molecular 
subtypes. RA-GCs were enriched in a subgroup of both of 
studies: CIN group in the TCGA study and microsatellite 
stable (MSS)/TP53-positive group in Cristescu et al. 
[14, 21]. Therefore, these classification approaches can 
be used to select RTK-amplified candidates. However, 
several hurdles including quality control, turn-around 
time, and cost issues can hamper the use of genome- or 
transcriptome-wide classification in daily clinical practice. 
To overcome these obstacles, we sought to develop a 
screening algorithm based on IHC and EBER-ISH methods 
that are robust, widely used in most pathology labs, 
and that also can be applied to formalin-fixed, paraffin-
embedded materials. In this IHC-based screening strategy, 
the availability of reliable and robust antibodies is critical. 
However, we failed to identify reliable antibodies for 
HER3 and FGFR2, which are other frequently amplified 
RTKs in GCs. The amplification of these RTKs can be 
accessed using fluorescence in situ hybridization [22–25], 
which can be time-consuming and expensive. In this 
respect, we evaluated the clinicopathologic characteristics 
of RA-GCs for three RTKs, EGFR, HER, and MET, and 
sought to develop a screening algorithm for the detection 
of a subgroup enriched with RA-GCs.
Figure 2: Comparison of recurrence-free survival and overall survival according to the group classification method. 
A. Recurrence-free survival according to putative molecular classification. EBV-positive and MMR-deficient subgroups showed favorable 
prognosis. However, pGS and pCIN subgroups showed relatively poor recurrence-free survival. Separate analysis of pGS and pCIN 
subgroups showed no significant difference between the two subgroups (P = 0.511). B. Recurrence-free survival according to histologic-
molecular classification. On separate analysis of D-pGS and I-pCIN subgroups, the I-pCIN subgroup showed a trend toward longer 
recurrence-free survival (P = 0.069). C. Overall survival according to the putative molecular classification. D. Overall survival according 
to the histologic-molecular classification.
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HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Sex Male 1 1 1 1
Female 1.028 (0.836-1.263) 0.797 0.973 (0.812-1.166) 0.768 1.028 (0.836-1.264) 0.796 0.972 (0.811-1.164) 0.758
Age (years) < 60 1 1 1 1
≥ 60 1.057 (0.865-1.293) 0.588 1.556 (1.307-1.853) < 0.001 1.055 (0.862-1.290) 0.605 1.554 (1.306-1.850) < 0.001
Location Lower third 1 1 1 1
Upper and 
mid-third 1.075 (0.881-1.311) 0.477 1.259 (1.060-1.495) 0.009 1.079 (0.885-1.316) 0.453 1.264 (1.064-1.501) 0.008
Size ≤ 5 cm 1 1 1 1
> 5 cm 1.282 (1.043-1.575) 0.018 1.197 (0.999-1.433) 0.051 1.284 (1.045-1.579) 0.017 1.201 (1.002-1.438) 0.047
Histology Differentiated 1 1 1 1




mixed 1 1 1 1
Diffuse 1.361 (1.050-1.763) 0.020 1.232 (0.989-1.534) 0.063 1.332 (1.002-1.770) 0.048 1.203 (0.944-1.534) 0.135
LVI Absent 1 1 1 1
Present 1.513 (1.230-1.860) < 0.001 1.550 (1.292-1.859) < 0.001 1.523 (1.240-1.872) <0.001 1.566 (1.306-1.877) < 0.001
LNM Absent 1 1 1 1
Present 1.212 (0.755-1.946) 0.427 1.426 (1.001-2.030) 0.049 1.227 (0.764-1.971) 0.394 1.426 (1.001-2.031) 0.050
Pathologic 
T stage T2 and T3 1 1 1 1
T4 1.678 (1.329-2.119) <0.001 1.603 (1.312-1.959) < 0.001 1.669 (1.323-2.107) <0.001 1.592 (1.303-1.944) < 0.001
Overall stage II and III 1 1 1 1
IV 2.657 (1.726-4.090) < 0.001 1.860 (1.345-2.573) < 0.001 2.644 (1.717-4.072) <0.001 1.854 (1.340-2.565) < 0.001
p53 IHC Wild-type pattern 1 1 1 1
Mutant pattern 1.401 (0.780-2.513) 0.259 1.420 (0.886-2.277) 0.146 0.973 (0.708-1.337) 0.865 0.973 (0.750-1.261) 0.834
RTK IHC Negative 1 1 1 1
Positive* 0.930 (0.673-1.286) 0.662 0.822 (0.625-1.083) 0.163 0.930 (0.672-1.285) 0.659 0.817 (0.621-1.075) 0.149
RTK gene 
amplification
Negative 1 1 1 1
Amplified** 1.130 (0.749-1.706) 0.559 1.160 (0.816-1.649) 0.408 1.126 (0.746-1.699) 0.573 1.155 (0.811-1.642) 0.422
Classification 
system*** EBV-positive 1 1 1 1
MMR-deficient 1.290 (0.700-2.378) 0.415 1.573 (0.937-2.641) 0.086 1.298 (0.703-2.397) 0.405 1.593 (0.947-2.677) 0.079
pGS / D-pGS 2.325 (1.332-4.060) 0.003 2.555 (1.578-4.136) < 0.001 2.072 (1.172-3.662) 0.012 2.274 (1.378-3.752) 0.001
pCIN / I-pCIN 1.472 (0.784-2.764) 0.229 1.573 (0.918-2.695) 0.099 1.934 (1.141-3.277) 0.014 2.100 (1.327-3.324) 0.002
HR: hazard ratio; CI: confidence interval; LVI: lymphovascular invasion; LNM: lymph node metastasis; RTK: receptor tyrosine kinase; MMR: 
mismatch repair gene related; pGS: putative genome stable; pCIN: putative chromosome instability; D-pGS: diffuse-putative genome stable; I-pCIN: 
intestinal-putative chromosome instability
* Defined as 2+ or 3+ for any of EGFR, HER2, or MET by IHC.
** Defined as amplification of any of EGFR, HER2, or MET by SISH.
***Putative molecular classification was categorized as EBV-positive, MMR-deficient, pGS and pCIN subgroup. Histologic-molecular classification was 
categorized as EBV-positive, MMR-deficient, D-pGS and I-pCIN subgroup.
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RA-GCs were associated with intestinal or mixed 
type by Lauren classification, negativity in EBER-ISH, 
and MMR-proficient and p53 mutant-pattern in IHC; 
these features are concordant with the findings of a 
previous genome-wide study [14]. From these findings, we 
established a histologic-molecular classification system 
using Lauren classification and the results of IHC and in 
situ hybridization. This classification system showed high 
sensitivity for detecting RA-GCs. Interestingly, overall 
survival of the subgroups based on histologic-molecular 
classification were similar to those of MSI, MSS/TP53-
positive, and MSS/TP53-negative groups classified by 
Cristescu et al. [21], except for the EBV-positive subgroup 
of our study and the MSS/EMT group of the report by 
Cristescu et al. [21].
Although several studies have reported that 
overexpression or amplification of RTKs is associated 
with a poor prognosis [11, 15, 16], we could not find 
any association with prognosis for EGFR, HER2, and 
MET overexpression/positivity or amplification and did 
not observe any difference between RA-GCs and non-
RA-GCs in this study. The effects of RTK status on 
patient prognosis are presumed to vary depending on 
the proportion of EBV-positive or D-pGS patients in the 
study population. Because we found a negative correlation 
between EGFR positivity and EBV-positive GCs and a 
tendency of negative correlation between HER2 positivity 
and EBV positivity (Table 1), the favorable prognosis 
of EBV-positive GCs might have confounding effects 
on the survival analysis of GCs with EGFR and HER2 
overexpression. That is, if the proportion of EBV-positive 
GCs increases in one study population, the EGFR or 
HER2-overexpressing/positive group might be interpreted 
as showing a worse prognosis. Inversely, as there is a 
negative relationship between RTK amplification and the 
D-pGS subgroup (Table 3), if the proportion of the D-pGS 
group increases, patients with RTK-amplified GC might 
show a more favorable prognosis. Thus, in the prognostic 
evaluation of RA-GCs, the influence of EBV-positive and 
D-pGS subgroups should be considered.
Most RA-GCs belonged to the I-pCIN subgroup 
in histologic-molecular classification. However, there 
were 13 cases that belonged to other subgroups: two 
EBV-positive GCs, seven MMR-deficient GCs, and four 
Figure 3: Proposed screening algorithm for the identification of RA-GCs.
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D-pGS GCs. These 13 cases consisted of five EGFR-
amplified and seven HER2-amplified GCs, and one case 
with co-amplification of EGFR and MET. The presence 
of these 13 RA-GCs could be a key limitation of our 
screening algorithm. Although these patients also could be 
candidates for RTK-targeted therapy, we believe that our 
classification approach is still valuable. A recent clinical 
trial using programmed death 1 blockade, pembrolizumab 
improved outcomes of MMR-deficient colon cancer 
patients [26]. EBV-positive GCs have shown frequent 
amplification of the programmed death ligand 1 (PDL-1) 
gene and overexpression of PDL-1 in tumor cells [14, 
27]. Therefore, we speculate that patients with EBV-
positive and MMR-deficient GC might be candidates for 
immunotherapy using immune checkpoint modulators 
such as pembrolizumab.
In addition to the presence of EGFR- and HER2-
amplified cases in non I-pCIN subgroups, our classification 
system showed quite low specificity (32.9% for RTK IHC 
and 34.2% for RTK gene amplification). This may be due 
to the presence of other RTKs such as HER3, FGFR1, 
and FGFR2 and downstream molecules such as PIK3CA 
or PTEN of the RTK pathway [14]. For these RTKs or 
targetable molecules, an optional target sequencing 
strategy using next generation sequencing (NGS) could 
be considered (Figure 3).
Although HER2 3+ expression on IHC has been 
accepted as a sufficient indicator for trastuzumab-
based chemotherapy, the treatment response and 
clinical outcomes can be affected by the level of HER2 
amplification [28]. Therefore, we included SISH 
confirmation for HER2 3+ cases as an optional assay 
in the proposed screening algorithm, which may be 
informative for predicting response. For EGFR or MET, 
the concordance between 3+ expression on IHC and 
gene amplification and the copy number effect on the 
prediction of response in targeted therapy remain to be 
elucidated. Therefore, SISH confirmation for MET or 
EGFR 3+ cases was included as an essential step in the 
algorithm. Cases with no overexpression or amplification 
of EGFR, HER2, and MET in IHC or SISH can be 
applied to target sequencing to find alterations in other 
RTKs or RTK-related genes. In this respect, the proposed 
screening algorithm can provide a stepwise approach 
for the identification of RTK gene amplification in a 
clinically feasible and cost-effective way by screening 
with IHC, validation of equivocal cases by IHC via in 
situ hybridization, and then target sequencing for negative 
cases.
Despite the advantages mentioned above, this study 
has several limitations. First, IHC and SISH of RTKs were 
performed using tissue microarrays (TMAs), raising the 
possibility of heterogeneity of RTKs in IHC and SISH 
[29]. An up to 30% rate of tumor heterogeneity on HER2 
IHC has been reported in GCs [30, 31]. At the time of 
TMA construction, we selected the most representative 
area of each case and used two relatively large cores 
(3 mm) to reduce the limitations related to tumor 
heterogeneity. Despite this effort, tumor heterogeneity 
might still influence our results for the three RTKs.
Second, genetic studies for TP53 mutation and MSI 
status were not performed, so there might be differences 
between IHC results of p53 and MMR proteins and the 
results of genetic studies. However, several studies 
have validated the high accordance rate between IHC 
and genetic study results for p53 and MMR proteins. In 
ovarian cancer, p53 IHC showed significant correlation 
with TP53 mutation status in cases showing complete 
loss of nuclear expression or strong and diffuse nuclear 
expression in more than 60% of tumor cells [32]. In 
colon cancer, the concordance rate between IHC of MMR 
proteins and PCR-based analysis has been reported to be 
as high as 98.6% [33–36]. Thus, according to the National 
Comprehensive Cancer Network guideline for colon 
cancer, IHC for MMR proteins has been introduced as an 
alternative method for detecting MSI-H-type colon cancer 
[37]. In GC, several studies have demonstrated high 
concordance between these two methods [21, 38, 39]. We 
also recently validated the high sensitivity and specificity 
of the IHC approach for MSI detection in GC [40]. Thus, 
we believe that IHC for p53 and MMR proteins can be a 
cost-effective modality for the prediction of genetic status 
in GC.
In conclusion, RA-GCs showed unique clinico 
pathologic characteristics: occurrence in older patients, 
differentiated histology, intestinal or mixed type by Lauren 
classification, presence of LVI, and p53 mutant-pattern. 
Histologic-molecular classification based on histologic 
type, IHC, and EBER-ISH profiles showed 87.5% 
sensitivity for the identification of RA-GCs. According 
to the proposed screening algorithm based on histologic-
molecular classification, RA-GCs can be identified in a 
cost-effective way. The positively screened cases might be 
candidates for clinical trials for the development of new 
targeted therapies; the negatively screened ones can be the 
candidates for the investigation of novel RTK genes through 
additional studies such as NGS.
MATERIALS AND METHODS
Case selection and tissue microarray 
construction
Tissue specimens from 993 consecutive AGC 
patients who underwent radical gastrectomy from 2000 to 
2003 at Severance Hospital were used in this study. Cases 
that were treated with neoadjuvant chemotherapy were 
excluded. This study was approved by the Institutional 
Review Board of Severance Hospital, Seoul, Republic of 
Korea (4-2015-0616). Various clinicopathologic factors, 
including age at operation, sex, tumor size and location, 
and clinical follow-up data were obtained by medical 
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record review. RFS time was calculated from the date of 
curative resection to the date of the first locoregional or 
systemic recurrence, or death without any type of relapse. 
OS time was calculated from the date of curative resection 
to the date of the last follow-up or death from any cause.
Several pathologic factors, including tumor histology, 
tumor type by Lauren classification, LVI, perineural 
invasion, and pathologic TNM staging according to the 7th 
American Joint Committee on Cancer criteria were obtained 
from the slide review by two individual pathologists (C. 
K. Park and H. Kim). Tumor histology was classified as 
differentiated and undifferentiated based on Japanese gastric 
cancer treatment guidelines 2010 [41]. Two cores were 
extracted from a representative tumor area of each case for 
TMA construction as previously described [40, 42]. For the 
evaluation of gene amplification via SISH, separate TMAs 
were constructed for cases showing 2+ or 3+ EGFR, HER2 
and MET expression on IHC.
Immunohistochemistry and evaluation
Four-micrometer tissue sections from TMA recipient 
blocks were used for IHC. IHC was performed using 
the Ventana Discovery XT automated staining system 
(Ventana Medical Systems, Inc., Tucson, AZ, USA) with 
primary antibodies (Table 5) as previously described 
[40, 42].
Immunostained slides were evaluated by two 
individual pathologists (C. K. Park and H. Kim) and 
results were interpreted as follows: cases showing 
complete loss of MLH1/ PMS2 or MSH2/MSH6 in tumor 
cells were regarded as MMR-deficient and all other cases 
were considered MMR-proficient. For p53, cases were 
classified as p53 mutant-pattern (cases with complete 
loss of expression or strong nuclear expression in more 
than 50% of tumor cells) and p53 wild-pattern (all other 
cases). Expression of EGFR, HER2, and MET was scored 
according to Hofmann’s criteria [30]. Cases scored as 2+ 
or 3+ were considered positive.
In situ hybridization and evaluation
SISH was performed on cases scored as 2+ or 3+ 
in IHC for EGFR, HER2, and MET using the Ventana 
Benchmark XT (Ventana Medical Systems, Inc.) as 
previously described [12, 27]. In brief, INFORM EGFR, 
HER2, and MET DNA Probe (Ventana Medical Systems, 
Inc.) and INFORM Chromosome 7 and 17 Probe (Ventana 
Medical Systems, Inc.) were visualized on the same slides 
according to the manufacturer’s protocols. EBER-ISH 
was performed in all cases as previously described [42]. 
As previously described, cases showing diffuse strong 
positivity in the nuclei of all tumor cells were defined as 
EBER-ISH-positive [43].
SISH slides were reviewed by two individual 
pathologists (C. K. Park and H. Kim) and RTK gene 
signals were counted in at least 60 tumor cells per TMA 
core using a light microscope with ×40 objective. In some 
tumor cells, clusters of signals showing many copies of 
RTK genes were identified. According to the interpretation 
guide for Ventana INFORM HER2 DNA probe (Ventana 
Medical Systems, Inc.), small clusters were counted 
as 6 signals and large clusters as 12 signals. Gene-to-
chromosome ratio and copy numbers per nuclei of each 
RTK gene were calculated. A gene-to-chromosome ratio 
greater than 2.0 was considered amplification. Cases 
showing amplification of any RTK genes in SISH were 
classified as RA-GCs.
Subgrouping of AGCs
All AGCs were divided into four subgroups using 
two classification systems. First, all cases were classified 
by putative molecular classification based on findings 
of the TCGA study [14]. Each subgroup was defined 
as follows: (1) EBV-positive: EBER-ISH positive; (2) 
MMR-deficient: EBER-ISH negative and MMR-deficient; 
(3) pGS: EBER-ISH negative, MMR-proficient and 
p53 wild-pattern: and (4) pCIN: EBER-ISH negative, 
Table 5: Antibodies used for immunohistochemical staining
Antibody Source Clone Dilution
MLH1 Roche, Basel, Switzerland M1 Ready to use
MSH2 Roche, Basel, Switzerland G219-1129 Ready to use
MSH6 Cell Marque, Rocklin, CA, USA 44 1:100
PMS2 Cell Marque, Rocklin, CA, USA MRQ28 1:40
p53 Novocastra, Newcastle, UK DO7 1:300
EGFR Cell signaling, Danvers, MA, USA Tyr992 1:200
HER2 Roche, Basel, Switzerland 4B5 Ready to use
c-MET Roche, Basel, Switzerland SP44 Ready to use
MLH1: MutL homolog 1; MSH2: MutS protein homolog 2; MSH6: MutS homolog 6; PMS2: Postmeiotic segregation 
increased 2; EGFR: epidermal growth factor receptor; HER2: human epidermal growth factor receptor-2
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MMR-proficient and p53 mutant-pattern. In addition, 
we classified all cases into another four subgroups based 
on Lauren classification, MMR proteins and p53 IHC 
results, and EBER-ISH result. These four subgroups 
were defined as follows: (1) EBV-positive: EBER-
ISH positive; (2) MMR-deficient: EBER-ISH negative 
and MMR-deficient; (3) D-pGS: EBER-ISH negative, 
MMR-proficient, p53 wild-type pattern, and diffuse type 
by Lauren classification; and (4) I-pCIN (p53 mutant-
pattern): EBER-ISH negative, MMR-proficient, and 
p53 mutant-pattern with regardless of histologic type 
by Lauren classification, and I-pCIN (p53 wild-pattern): 
EBER-ISH negative, MMR-proficient, p53 wild-pattern 
and intestinal or mixed type by Lauren classification. We 
designated this system histologic-molecular classification.
Statistical analysis
Statistical calculation was performed with SPSS 
version 21.0 (IBM, Chicago, IL, USA). Cross-table 
analysis (chi-square test) or Fisher’s exact test was used 
to evaluate the relationship between IHC/SISH results and 
variable clinicopathologic factors. For the comparison of 
patient age, the student’s t test was used. RFS and OS 
were estimated by the Kaplan-Meier method with log-rank 
test. Multivariate regression was analyzed using the Cox 
proportional hazards model. Significance statements refer 
to P-values of two-tailed tests < 0.05.
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